CHROMagar™ Candida Plus

For detection and differentiation of major clinical *Candida* species, including *C. auris*





Candida: A Growing Threat listed or

Overview

Over the past decade, infections caused by *Candida* species have risen, largely due to an increasing number of vulnerable individuals.

The WHO recently highlighted *Candida albicans*, *Candida auris* and *Candida glabrata* as priority pathogens, with *C. albicans* leading global candidemia cases.

Additionally, *Candida auris*, an emerging multidrugresistant pathogen associated to nosocomial infections, presents detection challenges.

Pathogenesis








Candida spp.: Data and Insights

72% of global *Candida* incidence is attribued to *C. albicans*, *C. glabrata* and *C. tropicalis*, according to mutiple studies¹

+ 150 million

~ 200,000 deaths ²

~ **\$2 billion**losses in healthcare in U



Candida auris: The Emerging Superbug



Recent reports indicate a significant rise in *Candida auris* infections in one year :

96%


increase in *Candida auris* cases has been reported in Europe.³

61%

increase in *Candida auris* cases has been reported in United States of America⁴

n the WHO Fungal Priority

CHROMagar™ Candida Plus is the first chromogenic isolation medium to detect and differentiate *C. auris* in addition to other major clinical *Candida* species such as *C. albicans, C. tropicalis, C. glabrata* or *C. krusei*.



Medium performance



EASY TO READ:

The medium is highly effective in differentiating various *Candida* species based on colony color and morphology.



DETECTION OF CANDIDA AURIS:

CHROMagar™ Candida Plus is particularly useful for identifying Candida auris, a multidrug-resistant species that poses significant challenges in healthcare settings



COST-EFFECTIVE

Using CHROMagar™ Candida Plus reduces the need for multiple tests or specialized media for differentiating *Candida* species, lowering the overall costs



HIGH SENSITIVITY AND SPECIFICITY:

The medium provides high sensitivity and specificity for differentiating clinically important *Candida* species, making it a reliable tool for diagnostic laboratories.



SAMPLES:

Swabs from skin, throat, ears, vagina as well as sputum,



RESULTS:

Can be interpreted within 24/48h of aerobic incubation at 30-37 °C

- ¹ Riera et al. 2022. Antibiotics (Basel). , Richardson et al. 2022. Pathogens. Fuller et al. 2019. J Antimicrob Chemother. Bilal et al. 2022. Virulence. Morii et al. 2014. Hnfect Chemother, Mirhendi et al. 2020. Medical Mycology, Schmalreck et al. 2012. Mycoses
- Richardson et al. 2022. Pathogens
- ³ Kohlenberg et al.2022.Eurosurveillance
- CDC Candida auris
- ⁵ Mulet Bayona et al. 2020. Diagn Microbiol Infect Dis

Clinical Microbiology: Empowering Detection

CHROMagar™ has developed a range of selective culture media for the rapid detection of clinically relevant pathogens, enhancing diagnostic speed and accuracy for better patient outcomes.



CHROMagar™ Acinetobacter



CHROMagar™ Orientation



CHROMagar™ **STEC**



CHROMagar™ B.cepacia



CHROMagar™ Salmonella



CHROMagar™ Strep A



CHROMagar™ C.difficile



CHROMagar™ Serratia



CHROMagar™ Strep B



CHROMagar™ Campylobacter



CHROMagar™ Staph aureus



LIM RambaQUICK™ Strep B

ASK YOUR LOCAL DISTRIBUTOR FOR MORE INFORMATION

Reference contact:



The Chromogenic Media Pioneer

CHROMagar.com

CHROMagar, 29 avenue George Sand, 93210 La Plaine Saint-Denis, France For more informations about our products and technical documents, please refer to our website. © 2024 CHROMagar LF-EXT-095-EN Version 1.0